Physician profile
Serena Mraz
NPI 1518911395
$508,668.13
in general payments reported to CMS, 2019-2025
31 companies · $39K in 2025
The $39K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126K · 2020: $65K · 2021: $99K · 2022: $91K · 2023: $14K · 2024: $74K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Food and Beverage: $7,291 · Consulting Fee: $6,750 · Travel and Lodging: $5,063 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,625.00 |
| Food and Beverage | $7,291.39 |
| Consulting Fee | $6,750.00 |
| Travel and Lodging | $5,063.13 |
| Education | $251.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $301,023.91 | 2019-2025 | Nemluvio |
| Abbvie INC. | $85,473.29 | 2019-2025 | |
| Allergan, INC. | $78,989.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $34,085.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,011.92 | 2021-2023 | Sotyktu |
| Helsinn Therapeutics (U.S.), INC. | $1,482.00 | 2020 | |
| Janssen Biotech, INC. | $995.62 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $622.80 | 2023-2025 | Siliq, Targretin, Cabtreo |
| Genzyme Corporation | $553.70 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $428.08 | 2019-2021 | |
| Pfizer INC. | $273.37 | 2019-2025 | |
| Amgen INC. | $237.91 | 2019-2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $233.46 | 2020-2023 | Ilumya |
| Modernatx, INC. | $187.50 | 2022 | |
| Ucb, INC. | $176.52 | 2019-2025 | Bimzelx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $131.62 | 2024 | |
| Lilly USA, LLC | $121.07 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $92.40 | 2025 | Zoryve |
| Fresenius Kabi USA, LLC | $86.61 | 2023-2024 | Idacio |
| Regeneron Healthcare Solutions, INC. | $82.46 | 2022-2024 | Dupixent |
| Strata Skin Sciences, INC. | $56.75 | 2022 | |
| Leo Pharma INC. | $53.89 | 2022-2024 | Adbry |
| Incyte Corporation | $49.81 | 2022-2024 | Opzelura |
| Revance Therapeutics, INC. | $45.99 | 2025 | Daxxify |
| Merz North America, INC. | $43.95 | 2019-2020 | |
| Celgene Corporation | $41.69 | 2019 | |
| Osiris Therapeutics INC. | $28.66 | 2019 | |
| Sandoz INC. | $24.28 | 2024 | Hyrimoz |
| Dermavant Sciences, INC. | $18.52 | 2023 | Vtama |
| Boston Scientific Corporation | $15.49 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serena Mraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.